Pelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026
Pelthos Therapeutics (NYSE American: PTHS) will report first quarter 2026 financial results on Thursday, May 14, 2026 and hold a conference call at 8:30 a.m. Eastern Time.
Rhea-AI Summary
Pelthos Therapeutics (NYSE American: PTHS) will report first quarter 2026 financial results on Thursday, May 14, 2026 and hold a conference call at 8:30 a.m. Eastern Time. The call includes a Q&A and will be accessible by phone (Conf. ID 13760399) and live webcast.
Dial-in numbers and the webcast link are provided for investor access.
Positive
- None.
Negative
- None.
Key Figures
- Earnings date
- May 14, 2026
- Scheduled Q1 2026 financial results release
- Conference call time
- 8:30 a.m. Eastern Time
- Q1 2026 results conference call start
- Toll-free dial-in
- 1-877-451-6152
- U.S. access number for earnings call
- International dial-in
- 1-201-389-0879
- International access number for earnings call
- Conference ID
- 13760399
- Identifier for Q1 2026 earnings call
Previous Earnings date Reports
-
Company scheduled Q4 and full-year 2025 results with an earnings call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to hold a conference call at 8:30 a.m. ET
DURHAM, N.C., May 01, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it will report first quarter 2026 financial results on Thursday, May 14, 2026. The company will hold a conference call followed by a question-and-answer period at 8:30 a.m. Eastern time.
Details for the conference call can be found below:
| Date: | Thursday, May 14, 2026 |
| Time: | 8:30 a.m. Eastern Time |
| Toll Free: | 1-877-451-6152 |
| International: | 1-201-389-0879 |
| Conf. ID: | 13760399 |
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1761761&tp_key=d31924f2e0
About Pelthos Therapeutics
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI™ (berdazimer) topical gel,
Contacts
Investors:
LifeSci Advisors, LLC
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com
Media:
KWM Communications
Kellie Walsh
pelthos@kwmcommunications.com
(914) 315-6072
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.